Suppr超能文献

围手术期脉络膜上腔出血及其手术治疗:一项系统综述

Perioperative suprachoroidal hemorrhage and its surgical management: a systematic review.

作者信息

Ribeiro Margarida, Monteiro David Matos, Moleiro Ana Filipa, Rocha-Sousa Amândio

机构信息

Department of Ophthalmology, Unidade Local de Saúde de São João, Alameda Prof. Hernâni Monteiro, Porto, 4200-319, Portugal.

Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.

出版信息

Int J Retina Vitreous. 2024 Aug 21;10(1):55. doi: 10.1186/s40942-024-00577-x.

Abstract

PURPOSE

Suprachoroidal hemorrhage (SCH) is a rare but severely feared sight-threatening complication of intraocular surgery, and its management remains debatable. We intended to summarize the existing surgical management options regarding perioperative SCH, describing different techniques and their respective visual outcomes.

METHODS

A systematic literature search of articles published since 1st January 2011 until 31st December 2022 was performed using MEDLINE (PubMed) and Scopus. Eligibility criteria included the adult population with SCH related to intraocular surgery.

RESULTS

Thirty-eight studies enrolling 393 patients/eyes were assessed after a selection process among 525 records. We included 5 retrospective cohort studies, 15 case series and 18 case reports. We documented cases of acute SCH diagnosed intraoperatively and delayed SCH, treated until a maximum of 120 days after the diagnosis. Best corrected visual acuity at diagnosis was generally poor, with variable final visual outcomes. Techniques of external drainage with or without combined pars plana vitrectomy (PPV), type of endotamponade (if PPV performed), anterior chamber maintainer and reports of the use of recombinant tissue plasminogen activator were described.

CONCLUSION

To the best of our knowledge, this is the first systematic review assessing perioperative SCH and its surgical management. There is no standardized surgical approach of SCH and longitudinal intervention studies are lacking. To ensure that patients achieve the best possible visual outcome, prompt diagnosis and treatment are crucial. Therefore, further clinical research is on demand to improve the management of this clinical sight-threatening entity.

摘要

目的

脉络膜上腔出血(SCH)是一种罕见但令人极度恐惧的眼内手术严重并发症,其治疗方法仍存在争议。我们旨在总结关于围手术期SCH的现有手术治疗选择,描述不同技术及其各自的视力预后。

方法

使用MEDLINE(PubMed)和Scopus对2011年1月1日至2022年12月31日发表的文章进行系统文献检索。纳入标准包括与眼内手术相关的成人SCH患者。

结果

在525条记录中经过筛选后,评估了38项纳入393例患者/眼的研究。我们纳入了5项回顾性队列研究、15个病例系列和18例病例报告。我们记录了术中诊断的急性SCH和延迟性SCH的病例,治疗时间最长至诊断后120天。诊断时的最佳矫正视力通常较差,最终视力预后各不相同。描述了采用或不采用联合玻璃体切割术(PPV)的外引流技术、内填塞类型(如果进行了PPV)、前房维持器以及重组组织型纤溶酶原激活剂的使用报告。

结论

据我们所知,这是第一项评估围手术期SCH及其手术治疗的系统评价。目前尚无SCH的标准化手术方法,且缺乏纵向干预研究。为确保患者获得最佳视力预后,及时诊断和治疗至关重要。因此,需要进一步的临床研究来改善对这种威胁视力的临床病症的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f981/11337774/7d430385a26e/40942_2024_577_Fig3_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验